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spectrometric assay for propafenone and its application to a pharmacokinetic study of propafenone
administered as a new propafenone hydrochloride sustained-release capsule (SR-test), as an instant-release
tablet (IR-reference) and as the market leader sustained-release capsule (Rythmol, SR-reference) in male
beagle dogs (n¼8). In Study A comparing SR-test with IR-reference in a crossover design Tmax and t1/2 of
propafenone for SR-test were signiﬁcantly higher than those for IR-reference while Cmax and AUC were
lower demonstrating the sustained release properties of the new formulation. In Study B comparing SR-
test with SR-reference the observed Cmax and AUC of propafenone for SR-test (124.57140.0 ng/mL and
612.07699.2 ng·h/mL, respectively) were higher than for SR-reference (78.52772.92 ng/mL and
423.67431.6 ng·h/mL, respectively) although the differences were not signiﬁcant. Overall, the new
formulation has as good if not better sustained release characteristics to the market leader formulation.
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Pharmacokinetics of propafenone hydrochloride SR capsules in dogs 751. Introduction
Atrial ﬁbrillation (AF) is a common type of arrhythmia that can
cause symptoms such as palpitations, chest tightness and dizziness.
It also poses a serious risk of thromboembolism which signiﬁ-
cantly increases the incidence of stroke and overall mortality. It is
therefore of great importance to improve both drug and non-drug
therapy of AF. Although non-drug therapy with pacemakers and
deﬁbrillators has made a signiﬁcant progress, drug treatment is still
the mainstay for the prevention and treatment of AF with evident
advantages such as convenience, good patient compliance and
reduction in the complications associated with the condition1,2.
Propafenone is a potent and generally well-tolerated antiar-
rhythmic agent which has been shown to be effective against a
variety of cardiac arrhythmias particularly AF3,4. It works by
slowing the inﬂux of sodium into cardiac muscle cells with
additional activity as a β-adrenergic blocker and weak calcium
channel blocker. A sustained-release (SR) formulation of propa-
fenone hydrochloride was ﬁrst developed by Abbott Laboratories
and approved by the FDA in September 2003. The aim of SR
pharmacotherapy was to prolong the time to recurrence of
symptoms in patients with episodic (most likely paroxysmal or
persistent) AF who do not have structural heart disease5.
There are two genetically determined patterns of propafenone
metabolism. In over 90% of patients, the drug is rapidly and
extensively metabolized with an elimination half-life of 2–10 h by
CYP2D6, CYP3A4 and CYP1A2. In less than 10% of patients,
metabolism is slow with an elimination half-life of 10–32 h
because of their deﬁciency of CYP2D66. In extensive metaboli-
zers, propafenone also undergoes saturable presystemic biotrans-
formation such that its bioavailability is both dose and dosage
form dependent7–10. Propafenone exhibits a high degree of inter-
subject variability in pharmacokinetic parameters following both
single and multiple dose administration probably due to the wide
range of CYP2D6 activity11.
According to the literature, the most common adverse effects
seen with propafenone are neurologic (visual blurring, paresthe-
sias, and dizziness) and gastrointestinal (constipation and nau-
sea)12. As expected, these adverse effects commonly occur around
the time of maximum blood concentration. An SR formulation
reduces this peak concentration and thereby reduces adverse
effects and the frequency of administration and increases patient
compliance. The objective of this investigation was to develop an
analytical method for the determination of propafenone in
dog plasma and evaluate the pharmacokinetic properties of a
new propafenone hydrochloride SR capsule in male beagle
dogs.2. Materials and methods
2.1. Chemicals and reagents
A propafenone hydrochloride 225 mg SR capsule (SR-test) was
manufactured by Lipin Pharmaceutical Industry (Xiamen, China).
Propafenone hydrochloride 50 mg immediate release tablets (IR-
reference) were supplied by Xinyi Pharmaceutical Industry
(Shanghai, China). The reference propafenone hydrochloride
225 mg SR capsule (SR-reference) was supplied by Abbott
Laboratories (Chicago IL, USA). The propafenone hydrochloride
standard (purity 99.9%) and quetiapine (purity 100.0%), for
internal standard (IS) use, were purchased from the NationalInstitutes for Food and Drug Control (Beijing, China). HPLC
grade methanol and acetonitrile were purchased from Merck
(Darmstadt, German). Formic acid and ammonium acetate were
of analytical grade and purchased from Nanjing Chemical Reagent
Co., Ltd. (Nanjing, China).
2.2. LC-MS assay
LC-MS was performed using an Agilent Technologies Series 1100 LC/
MSD SL system (Agilent Technologies, CA, USA). Isocratic chroma-
tography was carried out on a Hedara ODS-2 column (150 mm 2.1
mm, 5 mm, Jiangsu Hanbon Science & Technology Co., Ltd., China)
maintained at 38 1C using a mobile phase of methanol–0.15% aqueous
formic acid containing 5 mmol/L ammonium acetate (55:45, v/v) at a
ﬂow rate of 0.5 mL/min. The run time for each sample was 6 min.
Detection was by selective ion monitoring (SIM) of the parent ions of
propafenone at m/z 342.2 and IS at m/z 384.2.
2.3. Sample preparation
Aliquots of plasma (200 mL) to which IS solution was added were
vortex mixed for 30 s and then deproteinized by adding 1.4 mL
acetonitrile. After vortexing for 3 min, samples were centrifuged at
15,600 rpm for 5 min and aliquots of supernatant (100 mL) mixed
with 100 mL mobile phase and vortex-mixed for 5 s. The mixtures
were ﬁnally transferred into autosampler vials and 5 mL injected
into the LC-MS system.
2.4. Assay validation
Assay validation was carried out according to the FDA Guidance for
Validation of Bioanalytical Methods and included determination of
speciﬁcity, linearity over the concentration range 1.5–1500 ng/mL,
lower limit of quantitation (LLOQ), precision, accuracy, matrix
effects, extraction recovery and stability. Five replicates of quality
control (QC) samples at low, medium and high concentrations (4.0,
100 and 1200 ng/mL) and at the LLOQ (1.5 ng/mL) were analyzed
on three consecutive days to evaluate intra- and inter-day precision
and accuracy. Accuracy was determined by comparing the found
concentration to its nominal concentration and expressed as a
percentage; precision was expressed as relative standard deviation
(RSD)13,14. Recovery and matrix effects for propafenone were
determined by analyzing 6 replicates of QC samples. Corresponding
values for the IS at 5 ng/mL were determined in the same way.3. Animal studies
3.1. Study design
Two crossover studies (A and B) were carried out to compare the
SR-test and IR-reference formulations (Study A) and SR-test and
SR-reference formulations (Study B). In Study A, 8 male beagle
dogs (weight 9.9–11.2 kg) were randomly divided into two equal
groups and fasted overnight for 10 h before being administered
either the SR-test formulation (225 mg propafenone hydrochlor-
ide) or IR-reference formulation (200 mg propafenone hydrochlor-
ide) with 50 mL water. After a washout period of 7 days, the two
groups of dogs received the other formulation. The dogs were not
allowed to lie down for at least 2 h after dosing and were provided
with water thereafter. Food was provided 4 h after drug
Liping Pan et al.76administration. Blood samples (1.5 mL) were collected from an
elbow vein into heparinized tubes pre-dose and at 20, 40 min, 1,
1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 15 and 24 h post-dose. The
samples were centrifuged immediately at 4000 rpm for 10 min and
plasma separated and stored at 20 1C until analysis. Study B was
identical to Study A except dogs received either the SR-test
formulation or SR-reference formulation (both 225 mg propafe-
none hydrochloride).
3.2. Data analysis
Non-compartmental pharmacokinetic analysis was performed
using DAS 2.0 software (DASs; Professional Edition version
2.0, Drug and Statistics, Shanghai, China). The maximum plasma
concentration (Cmax) and the time to reach Cmax (Tmax) were
directly obtained from the data. AUC0–t was calculated by the
linear trapezoidal method and extrapolated to inﬁnity to obtain
AUC0–1 using the relationship AUC0–1¼AUC0–t þ Ct/K, where
Ct is the concentration at the last measurable time point and K is
the elimination rate constant. The terminal elimination half-life
(t1/2) was calculated as 0.693/K. CL/F was calculated as dose/
AUC0–1 and Vd/F was derived from Vd/F¼dose/(KAUC0–1).
The mean residence time (MRT) was estimated as MRT¼AUMC/
AUC where AUMC is the area under the ﬁrst moment curve.
Differences in pharmacokinetic parameters were tested by one-
way ANOVA.4. Results and discussion
4.1. Assay validation
Precision and accuracy of the assay are shown in Table 1 and
recovery and matrix effects are shown in Table 2.
The results in Table 1 demonstrate that intra- and inter-day
accuracy and precision were all within acceptable limits (85%–
100% for accuracy, 715% for precision). The recoveries ofTable 1 Precision and accuracy for the analysis of propafenone in d
Concentration (ng/mL) Precision
Added Measured Intra-day
1.533 1.58270.079 4.4
4.088 3.95270.196 5.2
102.2 106.270.8 0.2
1226 1242713 1.0
Data are mean7SD, n¼5; RSD: relative standard deviation; RE: relative e
Table 2 Recovery and matrix effects for the analysis of propafenon
Compound Concentration (ng/mL) Recovery
Mean (%)
Propafenone 4.088 99.1
102.2 101.3
1226 103.0
IS 5.330 100.8
Data are mean values, n¼6; RSD: relative standard deviation.propafenone at three concentration levels (4, 100 and 1200 ng/
mL) and of the IS at 5 ng/mL were all close to 100% (Table 2).
Results of the matrix effects study for propafenone and IS reveal
that there were no signiﬁcant matrix effects, indicating that no co-
eluting substance inﬂuenced the ionization of either the analyte or
IS.4.2. Pharmacokinetic studies
Pharmacokinetic parameters from Studies A and B are presented in
Table 3 with plasma concentration–time curves of propafenone
administered as SR-test and IR-reference formulations (Study A)
and as SR-test and SR-reference formulations are shown in Figs. 1
and 2, respectively.
In Study A, the Tmax of propafenone for the IR-reference was
1.570.7 h, indicating rapid absorption (Table 3). In comparison,
the Tmax of analyte for the SR-test was 4.172.6 h, representing a
2.7-fold increase. The mean t1/2 value for SR-test was 1.77-fold
greater than for IR-reference, indicating that elimination of
propafenone is prolonged in the SR formulation. Consistent with
these results, the Cmax of propafenone was considerably lower for
SR-test. However, a second absorption peak of propafenone
(presumably due to enterohepatic recycling) was higher for SR-
test than for IR-reference. Together these results indicate that SR-
test provides signiﬁcantly slower release of propafenone compared
with IR-reference.
Despite the evident slower release, the mean AUC0–24 of
propafenone for SR-test was obviously lower than that for IR-
reference suggesting a decrease in relative bioavailability of
propafenone from SR-test of 58.2%. This is possibly due to the
fact that the more gradual release of propafenone from SR-test
allows time for more ﬁrst pass metabolism to occur and avoids
the metabolic saturation to which the ﬁrst pass metabolism is
susceptible10,15,16.
In Study B, comparing the pharmacokinetics of propafenone
after oral administration of the SR-test and SR-referenceog plasma.
(RSD%) Accuracy (RE%)
Inter-day
7.5 4.0
3.5 2.3
0.1 3.4
1.5 0.8
rror.
e in dog plasma.
Matrix effect
RSD (%) Mean (%) RSD (%)
2.3 99.6 4.30
1.0 98.2 0.70
0.8 100.6 4.10
2.4 101.4 0.04
Table 3 Main pharmacokinetic parameters of propafenone in male beagle dogs obtained in Studies A and B.
Parameters Study A Study B
SR-test IR-reference SR-test SR-reference
Cmax (ng/mL) 175.97112.0 886.67736.4 124.57140.0 78.52772.92
Tmax (h) 4.172.6 1.570.7 1.871.5 3.473.8
t1/2 (h) 5.374.5 3.072.1 4.071.9 3.172.2
MRT (h) 6.872.2 2.770.9 5.971.8 7.273.3
CL/F (L/h) 641.67777.5 189.07153.7 846.87870.3 802.77774.3
Vd/F (L) 322773296 738.17511.8 430073549 924776638
AUC0–24 (ng·h/mL) 753.57502.8 180471402 612.07699.2 423.67431.6
AUC0–1 (ng·h/mL) 912.77763.3 183971436 660.47709.0 441.57437.8
Data are mean7SD, n¼8; RSD: relative standard deviation.
Figure 1 Plasma concentration-time curves of propafenone in a
crossover study of male beagle dogs after oral administration of the
SR-test and IR-reference formulations (Study A). Data are mean7SD
(n¼8). The unit of C is ng/mL.
Figure 2 Plasma concentration-time curves of propafenone in a
crossover study of male beagle dogs after oral administration of the
SR-test and SR-reference formulations (Study B). Data are mean7SD
(n¼8). The unit of the C is ng/mL.
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were higher than those for SR-reference but the differences were
not signiﬁcant. One reason for the lack of signiﬁcance is becausethe pharmacokinetics of propafenone in beagle dogs is nonlinear
and leads to high inter-individual variation in the pharmacokinetic
parameters for which the small number of dogs used in the studies
is insufﬁcient to compensate. Inter-subject variability in propafe-
none pharmacokinetics is known to be high in CYP2D6 extensive
metabolizers suggesting the high variability seen here is due to
CYP2D6 polymorphism rather than to the formulation.
The above discussion notwithstanding, the increased Tmax and
t1/2 of propafenone coupled with the considerably reduced Cmax
and the maintenance of an appreciable plasma concentration
demonstrate that the new SR formulation has improved sustained
release characteristics. It is anticipated therefore that SR-test could
offer sustained therapeutic beneﬁts and minimize adverse effects.
According to the Chinese Pharmacopoeia, a study of multiple dose
administration is now needed to further develop the sustained-
release formulation17.5. Conclusions
A new propafenone hydrochloride sustained release capsule has
been shown to exhibit good sustained release characteristics
despite providing lower relative bioavailability than an immediate
release tablet. The new formulation has also been shown to
provide as good if not better sustained release characteristics than
the market leader.References
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